Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Marike Visser, Matthew J. Zaya, Charles W. Locuson, Dawn M. Boothe & Dawn A. Merritt. (2019) Comparison of predicted intrinsic hepatic clearance of 30 pharmaceuticals in canine and feline liver microsomes. Xenobiotica 49:2, pages 177-186.
Read now
Read now
Nicolas Hohmann, Walter E. Haefeli & Gerd Mikus. (2016) CYP3A activity: towards dose adaptation to the individual. Expert Opinion on Drug Metabolism & Toxicology 12:5, pages 479-497.
Read now
Read now
Joanne A. Foster, J. Brian Houston & David Hallifax. (2011) Comparison of intrinsic clearances in human liver microsomes and suspended hepatocytes from the same donor livers: clearance-dependent relationship and implications for prediction of in vivo clearance. Xenobiotica 41:2, pages 124-136.
Read now
Read now
Shu-Feng Zhou, Jun-Ping Liu & Balram Chowbay. (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 41:2, pages 89-295.
Read now
Read now
H. C. Rawden, D. J. Carlile, A. Tindall, D. Hallifax, A. Galetin, K. Ito & J. B. Houston. (2005) Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans. Xenobiotica 35:6, pages 603-625.
Read now
Read now
M. Miura, K. Otani & T. Ohkubo. (2005) Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica 35:5, pages 455-465.
Read now
Read now
Slobodan Rendic. (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 34:1-2, pages 83-448.
Read now
Read now
Articles from other publishers (51)
Yoshiya Yamamura, Kouichi Yoshinari & Yasushi Yamazoe. (2023) Construction of a fused grid-based CYP2C19-Template system and the application. Drug Metabolism and Pharmacokinetics 48, pages 100481.
Crossref
Crossref
Jie Zhao, Sijie Liu, Clemens Alexander Wolf, Gerhard Wolber, Maria Kristina Parr & Matthias Bureik. (2022) Changes in Alprazolam Metabolism by CYP3A43 Mutants. Biomedicines 10:12, pages 3022.
Crossref
Crossref
Michael Mohutsky & Stephen D. Hall. 2021. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
51
88
.
Mohammad K. Parvez & Vikas Rishi. (2019) Herb-Drug Interactions and Hepatotoxicity. Current Drug Metabolism 20:4, pages 275-282.
Crossref
Crossref
Tom S. Chan, Hongbin Yu, Amanda Moore, Salman R. Khetani & Donald Tweedie. (2019) Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac. Drug Metabolism and Disposition 47:1, pages 58-66.
Crossref
Crossref
Bjoern Moosmann & Volker Auwärter. 2018. New Psychoactive Substances. New Psychoactive Substances
383
410
.
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
213
215
.
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
710
725
.
Jose Valdes, Douglas L. Boggs, Angela A. Boggs & Jose A. Rey. 2016. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
471
495
.
S. Keil, S. Iwersen-Bergmann, A. Müller & H. Andresen-Streichert. (2014) Pharmakokinetische Wechselwirkungen illegaler Drogen mit ArzneimittelnPharmacokinetic interactions between pharmaceutical and illegal drugs. Rechtsmedizin 24:2, pages 77-90.
Crossref
Crossref
Michael Mohutsky & Stephen D. Hall. 2014. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
57
91
.
Tom S. Chan, Hongbin Yu, Amanda Moore, Salman R. Khetani & Donald Tweedie. (2013) Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac. Drug Metabolism and Disposition 41:12, pages 2024-2032.
Crossref
Crossref
Bjoern Moosmann, Melanie Hutter, Laura M. Huppertz, Sascha Ferlaino, Lisa Redlingshöfer & Volker Auwärter. (2013) Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicology 31:2, pages 263-271.
Crossref
Crossref
Hadi Molanaei, Peter Stenvinkel, Abdul Rashid Qureshi, Juan Jesús Carrero, Olof Heimbürger, Bengt Lindholm, Ulf Diczfalusy, Ingegerd Odar-Cederlöf & Leif Bertilsson. (2011) Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation. European Journal of Clinical Pharmacology 68:5, pages 571-577.
Crossref
Crossref
Pierre Baumann & Christoph Hiemke. 2012. Metabolism of Drugs and Other Xenobiotics. Metabolism of Drugs and Other Xenobiotics
301
329
.
David E. Moody. 2012. Handbook of Drug Interactions. Handbook of Drug Interactions
25
116
.
Brian J. Kirby, Ann C. Collier, Evan D. Kharasch, Vaishali Dixit, Pankaj Desai, Dale Whittington, Kenneth E. Thummel & Jashvant D. Unadkat. (2011) Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6, and 2C9 by Ritonavir or Nelfinavir. Drug Metabolism and Disposition 39:12, pages 2329-2337.
Crossref
Crossref
Young Hee Choi, Young-Won Chin & Yoon Gyoon Kim. (2011) Herb-drug interactions: Focus on metabolic enzymes and transporters. Archives of Pharmacal Research 34:11, pages 1843-1863.
Crossref
Crossref
Xiao-Wu Chen, Erini S. Serag, Kevin B. Sneed & Shu-Feng Zhou. (2011) Herbal bioactivation, molecular targets and the toxicity relevance. Chemico-Biological Interactions 192:3, pages 161-176.
Crossref
Crossref
Myung Joo KANG, Woo Heon SONG, Byung Ho SHIM, Seung Youn OH, Hyun Young LEE, Eun Young CHUNG, Yesung SOHN & Jaehwi LEE. (2010) Pharmacologically Active Metabolites of Currently Marketed Drugs: Potential Resources for New Drug Discovery and Development. YAKUGAKU ZASSHI 130:10, pages 1325-1337.
Crossref
Crossref
Tatsuyuki Ohtsuka, Takahiro Yoshikawa, Kazumasa Kozakai, Yumi Tsuneto, Yasuhiro Uno, Masahiro Utoh, Hiroshi Yamazaki & Toshiyuki Kume. (2010) Alprazolam as an In Vivo Probe for Studying Induction of CYP3A in Cynomolgus Monkeys. Drug Metabolism and Disposition 38:10, pages 1806-1813.
Crossref
Crossref
Frederique Fenneteau, Patrick Poulin & Fahima Nekka. (2010) Physiologically Based Predictions of the Impact of Inhibition of Intestinal and Hepatic Metabolism on Human Pharmacokinetics of CYP3A Substrates. Journal of Pharmaceutical Sciences 99:1, pages 486-514.
Crossref
Crossref
Justas Dapkunas, Andrius Sazonovas & Pranas Japertas. (2009) Probabilistic Prediction of the Human CYP3A4 and CYP2D6 Metabolism Sites. Chemistry & Biodiversity 6:11, pages 2101-2106.
Crossref
Crossref
Olavi Pelkonen, Miia Turpeinen, Jukka Hakkola, Paavo Honkakoski, Janne Hukkanen & Hannu Raunio. (2008) Inhibition and induction of human cytochrome P450 enzymes: current status. Archives of Toxicology 82:10, pages 667-715.
Crossref
Crossref
Jeffrey C. Stevens, Sandra A. Marsh, Matthew J. Zaya, Karen J. Regina, Karthika Divakaran, Min Le & Ronald N. Hines. (2008) Developmental Changes in Human Liver CYP2D6 Expression. Drug Metabolism and Disposition 36:8, pages 1587-1593.
Crossref
Crossref
Rhonda Roedler, Melinda M Neuhauser & Scott R Penzak. (2016) Does Metronidazole Interact with CYP3A Substrates by Inhibiting Their Metabolism Through This Metabolic Pathway? Or Should Other Mechanisms Be Considered?. Annals of Pharmacotherapy 41:4, pages 653-658.
Crossref
Crossref
Annika Allqvist, Jun Miura, Leif Bertilsson & Rajaa A. Mirghani. (2007) Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. European Journal of Clinical Pharmacology 63:2, pages 173-179.
Crossref
Crossref
J Christopher Gorski. 2006. Herbal Supplements-Drug Interactions. Herbal Supplements-Drug Interactions
69
105
.
Thomas K. H. Chang, Jie Chen & Xiao Wei Teng. (2006)
DISTINCT ROLE OF BILOBALIDE AND GINKGOLIDE A IN THE MODULATION OF RAT CYP2B1 AND CYP3A23 GENE EXPRESSION BY
GINKGO BILOBA
EXTRACT IN CULTURED HEPATOCYTES
. Drug Metabolism and Disposition 34:2, pages 234-242.
Crossref
Crossref
. 2006. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions
3529
3530
.
. 2006. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions
2183
2195
.
Robert Lee PageIIII, Patrick M Klem & Christin Rogers. (2017) Potential Elevation of Tacrolimus Trough Concentrations with Concomitant Metronidazole Therapy. Annals of Pharmacotherapy 39:6, pages 1109-1113.
Crossref
Crossref
Agneta Wennerholm, Annika Allqvist, Jan-Olof Svensson, Lars L. Gustafsson, Rajaa A. Mirghani & Leif Bertilsson. (2005) Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of α- and 4-hydroxy metabolites in healthy subjects. European Journal of Clinical Pharmacology 61:2, pages 113-118.
Crossref
Crossref
Shufeng Zhou, Sui Yung Chan, Boon Cher Goh, Eli Chan, Wei Duan, Min Huang & Howard L McLeod. (2005) Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs. Clinical Pharmacokinetics 44:3, pages 279-304.
Crossref
Crossref
Annika Allqvist, Agneta Wennerholm, Jan-Olof Svensson & Rajaa A. Mirghani. (2005) Simultaneous quantification of alprazolam, 4- and α-hydroxyalprazolam in plasma samples using liquid chromatography mass spectrometry. Journal of Chromatography B 814:1, pages 127-131.
Crossref
Crossref
Aleksandra Galetin, Caroline Brown, David Hallifax, Kiyomi Ito & J. Brian Houston. (2004) UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES. Drug Metabolism and Disposition 32:12, pages 1411-1420.
Crossref
Crossref
Kiman Kim, Julie A. Johnson & Hartmut Derendorf. (2004) Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms. The Journal of Clinical Pharmacology 44:10, pages 1083-1105.
Crossref
Crossref
Jennifer Anke & Iqbal Ramzan. (2004) Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). Journal of Ethnopharmacology 93:2-3, pages 153-160.
Crossref
Crossref
Gonzalo Calvo, Consuelo García-Gea, Antonio Luque, Adelaida Morte, Rafael Dal-Ré & Manel Barbanoj. (2004) Lack of Pharmacologic Interaction Between Paroxetine and Alprazolam at Steady State in Healthy Volunteers. Journal of Clinical Psychopharmacology 24:3, pages 268-276.
Crossref
Crossref
Shufeng Zhou, Hwee-Ling Koh, Yihuai Gao, Zhi-yuan Gong & Edmund Jon Deoon Lee. (2004) Herbal bioactivation: The good, the bad and the ugly. Life Sciences 74:8, pages 935-968.
Crossref
Crossref
David E. Moody. 2004. Handbook of Drug Interactions. Handbook of Drug Interactions
3
88
.
John S. Markowitz, Jennifer L. Donovan, C. Lindsay DeVane, Laura Sipkes & Kenneth D. Chavin. (2003) Multiple-Dose Administration of Ginkgo biloba Did Not Affect Cytochrome P-450 2D6 or 3A4 Activity in Normal Volunteers. Journal of Clinical Psychopharmacology 23:6, pages 576-581.
Crossref
Crossref
Y. W. Francis Lam, Cara L. Alfaro, Larry Ereshefsky & Michael Miller. (2013) Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone. The Journal of Clinical Pharmacology 43:11, pages 1274-1282.
Crossref
Crossref
Judith Hall, Claudio A. Naranjo, Beth A. Sproule & Nathan Herrmann. (2003) Pharmacokinetic and Pharmacodynamic Evaluation of the Inhibition of Alprazolam by Citalopram and Fluoxetine. Journal of Clinical Psychopharmacology 23:4, pages 349-357.
Crossref
Crossref
Jennifer L. Donovan, C. Lindsay DeVane, Kenneth D. Chavin, Robin M. Taylor & John S. Markowitz. (2003)
Siberian Ginseng (
Eleutheroccus senticosus
) Effects on CYP2D6 and CYP3A4 Activity in Normal Volunteers
. Drug Metabolism and Disposition 31:5, pages 519-522.
Crossref
Crossref
J.L.C.M Dorne, K Walton & A.G Renwick. (2003) Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food and Chemical Toxicology 41:2, pages 201-224.
Crossref
Crossref
J. Andrew Williams, Barbara J. Ring, Varon E. Cantrell, David R. Jones, James Eckstein, Kenneth Ruterbories, Mitchell A. Hamman, Stephen D. Hall & Steven A. Wrighton. (2002) Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metabolism and Disposition 30:8, pages 883-891.
Crossref
Crossref
A. David Rodrigues, Gregory A. Winchell & Michael R. Dobrinska. (2013) Use of In Vitro Drug Metabolism Data to Evaluate Metabolic Drug‐Drug Interactions in Man: The Need for Quantitative Databases. The Journal of Clinical Pharmacology 41:4, pages 368-373.
Crossref
Crossref
Noriko Hirota, Kiyomi Ito, Takafumi Iwatsubo, Carol E. Green, Charles A. Tyson, Noriaki Shimada, Hiroshi Suzuki & Yuichi Sugiyama. (2001)
In Vitro
/
in Vivo
scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans
. Biopharmaceutics & Drug Disposition 22:2, pages 53-71.
Crossref
Crossref
R. Walter. 2001.
283
313
.
Jürgen Brockmöller, Julia Kirchheiner, Christian Meisel & Ivar Roots. (2000) Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 1:2, pages 125-151.
Crossref
Crossref